Agilon Health (NYSE:AGL) Trading Down 5.2% After Analyst Downgrade

Agilon Health, Inc. (NYSE:AGL - Get Free Report) shares traded down 5.2% during mid-day trading on Wednesday after Evercore ISI lowered their price target on the stock from $5.00 to $3.00. Evercore ISI currently has an in-line rating on the stock. Agilon Health traded as low as $2.26 and last traded at $2.27. 412,174 shares were traded during trading, a decline of 92% from the average session volume of 5,292,059 shares. The stock had previously closed at $2.39.

A number of other research firms have also weighed in on AGL. Citigroup raised shares of Agilon Health from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $3.25 to $5.00 in a research report on Friday, April 25th. Robert W. Baird cut their price objective on shares of Agilon Health from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Tuesday, April 15th. Wells Fargo & Company cut their price objective on shares of Agilon Health from $6.00 to $5.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Cowen reissued a "hold" rating on shares of Agilon Health in a research report on Tuesday, April 15th. Finally, Sanford C. Bernstein raised shares of Agilon Health from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $3.30 to $8.50 in a research report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Agilon Health has an average rating of "Hold" and a consensus target price of $4.71.

Hedge Funds Weigh In On Agilon Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its stake in Agilon Health by 49.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,541,549 shares of the company's stock worth $8,629,000 after buying an additional 1,498,524 shares during the period. Raymond James Financial Inc. purchased a new stake in Agilon Health during the fourth quarter worth approximately $33,000. Amundi grew its stake in Agilon Health by 2.9% during the fourth quarter. Amundi now owns 995,295 shares of the company's stock worth $1,891,000 after buying an additional 28,476 shares during the period. Wealthfront Advisers LLC purchased a new stake in Agilon Health during the fourth quarter worth approximately $51,000. Finally, Cibc World Markets Corp purchased a new stake in Agilon Health during the fourth quarter worth approximately $55,000.

Agilon Health Stock Down 3.5%

The firm's 50 day simple moving average is $2.44 and its 200-day simple moving average is $3.23. The company has a market capitalization of $923.11 million, a PE ratio of -3.78 and a beta of 0.16.

Agilon Health (NYSE:AGL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.04. Agilon Health had a negative net margin of 4.04% and a negative return on equity of 45.47%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the previous year, the firm earned ($0.02) earnings per share. Agilon Health's revenue for the quarter was down 4.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Agilon Health, Inc. will post -0.59 EPS for the current fiscal year.

Agilon Health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.